D.T.R.G awarded an NIH Grant
We are thrilled to announce that we have been awarded an NIH grant for an upcoming project, lead by Professor David O’Neal and Dr Dale Morrison and to be implemented by Dr Audrey Kong, a Research Fellow, Endocrinologist, and PhD candidate at Diabetes Technology Research Group and the University of Melbourne, and our D.T.R.G team members.
This study, “The Evaluation of Two Response Thresholds to Continuous Ketone Monitoring Information Minimising Ketosis in People with Type 1 Diabetes Treated with Dapagliflozin”, will investigate how we can safely extend the benefits of SGLT inhibitors to people with T1D.
SGLT inhibitors have transformed the management of Type 2 diabetes, offering improved glycaemic control and significant reductions in cardiovascular and renal complications. However, their use in T1D has been limited due to the risk of diabetic ketoacidosis (DKA). This study will evaluate whether continuous glucose and ketone monitoring (CGKM), combined with a tailored response algorithm, can help detect rising ketone levels early and prevent progression to DKA. Participants will be randomised to initiate remedial action at different ketone thresholds, with the goal of identifying the safest and most effective approach.
We would like to thank St Vincent’s Hospital Melbourne, Austin Health, The Royal Melbourne Hospital, and the Telethon Kids Institute for partnering with us for this study to bring this project to people with type 1 diabetes across Australia, and The Australian Centre for Accelerating Diabetes Innovations (ACADI) for funding our previous investigations that helped us secure this important grant.
This is a significant step forward in our mission to improve the lives of people with diabetes, and we look forward to sharing the results of this important project in the future.
D.T.R.G awarded an NIH Grant
We are thrilled to announce that we have been awarded an NIH grant for an upcoming project, lead by Professor David O’Neal and Dr Dale Morrison and to be implemented by Dr Audrey Kong, a Research Fellow, Endocrinologist, and PhD candidate at Diabetes Technology Research Group and the University of Melbourne, and our D.T.R.G team members.
This study, “The Evaluation of Two Response Thresholds to Continuous Ketone Monitoring Information Minimising Ketosis in People with Type 1 Diabetes Treated with Dapagliflozin”, will investigate how we can safely extend the benefits of SGLT inhibitors to people with T1D.
SGLT inhibitors have transformed the management of Type 2 diabetes, offering improved glycaemic control and significant reductions in cardiovascular and renal complications. However, their use in T1D has been limited due to the risk of diabetic ketoacidosis (DKA). This study will evaluate whether continuous glucose and ketone monitoring (CGKM), combined with a tailored response algorithm, can help detect rising ketone levels early and prevent progression to DKA. Participants will be randomised to initiate remedial action at different ketone thresholds, with the goal of identifying the safest and most effective approach.
We would like to thank St Vincent’s Hospital Melbourne, Austin Health, The Royal Melbourne Hospital, and the Telethon Kids Institute for partnering with us for this study to bring this project to people with type 1 diabetes across Australia, and The Australian Centre for Accelerating Diabetes Innovations (ACADI) for funding our previous investigations that helped us secure this important grant.
This is a significant step forward in our mission to improve the lives of people with diabetes, and we look forward to sharing the results of this important project in the future.